Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Carasent AB (publ)APXZF 79 EV-to-EBITDA is 19.87 as of Jul. 31, 2026, which is 5% below its 10-year median of 20.83. GuruFocus rates APXZF with a GF Score™ of 79/100 and a GF Value™ of $0.18. The stock has 3 warning signs investors should review. Among 509 Healthcare Providers & Services companies, Carasent AB (publ) ranks worse than 76.62% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Carasent AB (publ)'s enterprise value is $170.55 Mil.
Carasent AB (publ)'s EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was $8.58 Mil. Therefore, Carasent AB (publ)'s EV-to-EBITDA for today is 19.87.
The historical rank and industry rank for Carasent AB (publ)'s EV-to-EBITDA or its related term are showing as below:
APXZF'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -330.51 Med: 20.83 Max: 1195.6
Current: 19.56
During the past 13 years, the highest EV-to-EBITDA of Carasent AB (publ) was 1195.60. The lowest was -330.51. And the median was 20.83.
APXZF's EV-to-EBITDA is ranked worse than 76.62% of 509
companies
in the Healthcare Providers & Services industry
Industry Median: 11.04
vs APXZF: 19.56
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Carasent AB (publ) (OTCPK:APXZF) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Carasent AB (publ)'s PE Ratio (TTM) for today is calculated as:
Carasent AB (publ)'s share price for today is $0.15.
Carasent AB (publ)'s Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.066.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Carasent AB (publ)'s EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Health Information Services subindustry, Carasent AB (publ)'s EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Carasent AB (publ) EV-to-EBITDA vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Carasent AB (publ)'s EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Carasent AB (publ)'s EV-to-EBITDA falls into.
Carasent AB (publ)'s current Enterprise Value is $170.55 Mil.
Carasent AB (publ)'s EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $8.58 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Carasent AB (publ) (APXZF) has a EV-to-EBITDA of 19.87 as of Jul. 31, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Carasent AB (publ). This is near median its historical median of 20.83. According to the industry distribution chart, Carasent AB (publ) ranks #390 out of 509 companies in the Healthcare Providers & Services industry, placing it in the top 76.6%.
Is Carasent AB (publ)'s EV-to-EBITDA too high?
Carasent AB (publ)'s current EV-to-EBITDA of 19.87 is near median its 10-year median of 20.83. The Healthcare Providers & Services industry median EV-to-EBITDA is 11.04. Carasent AB (publ)'s value of 19.87 is 80% above this industry median. Based on the distribution chart, Carasent AB (publ) ranks #390 out of 509 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, Carasent AB (publ) has a GF Score™ of 79/100, reflecting its overall financial health beyond just this single metric.
How does Carasent AB (publ)'s EV-to-EBITDA compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, Carasent AB (publ) ranks #390 out of 509 companies for EV-to-EBITDA. This places Carasent AB (publ) in the lower half of its industry. The industry median EV-to-EBITDA is 11.04. Carasent AB (publ)'s value of 19.87 is 80% above this benchmark. While the company's 10-year median is 20.83 vs. the industry median of 11.04, Carasent AB (publ) has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Healthcare Providers & Services company?
The median EV-to-EBITDA among Healthcare Providers & Services companies is 11.04, based on 509 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Carasent AB (publ)'s current EV-to-EBITDA of 19.87 is 80% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Carasent AB (publ). For the Healthcare Providers & Services industry, the median EV-to-EBITDA is 11.04 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Carasent AB (publ)'s current EV-to-EBITDA is 19.87, which is near median its own 10-year median of 20.83. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Carasent AB (publ) stock overvalued right now?
Carasent AB (publ) (APXZF) has a current EV-to-EBITDA of 19.87. The stock's GF Value™ is $0.18, compared to a current price of $0.15 — trading 16.7% below its estimated fair value. The current EV-to-EBITDA is 19.87, which is near median its 10-year median of 20.83 and 80% above the Healthcare Providers & Services industry median of 11.04. Carasent AB (publ)'s overall GF Score™ is 79/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Carasent AB (publ) (APXZF), the current EV-to-EBITDA is 19.87 as of Jul. 31, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Carasent AB (publ) (APXZF) Overvalued in 2026?
Based on GuruFocus' analysis, Carasent AB (publ) stock appears to be undervalued.
The current stock price of $0.15 is trading 16.7% below its estimated GF Value™ of $0.18.
Key valuation signals for APXZF:
EV-to-EBITDA: 19.87 (near median its 10-year median of 20.83)
GF Value™: $0.18 vs. price of $0.15 (16.7% below fair value)
Industry Position: 80% above the Healthcare Providers & Services median (#390 of 509)
No single metric tells the full story. See the APXZF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Carasent AB (publ) Formerly Carasent AB is a comprehensive provider of cloudbased EHR solutions and platform services for various organizations within the healthcare sector. With Webdoc as the main product, the group offers a broad ecosystem of services, including solutions for patient communication and business intelligence. Geographically, the company operates in the Nordic region and Germany. It derives maximum revenue from Nordic Region. The solutions provides by the group are: Webdoc; Metodika; Medrave; HPI plustoo; Ad Curis; Ad Opus; Webcur; Data-AL; and Data-Cur.
79GF Score
Get the complete analysis for APXZF
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
APXZF has been successfully added to your 
